Home' Australian Pharmacist : Australian Pharmacist April 2014 Contents Australian Pharmacist April 2014 I ©Pharmaceutical Society of Australia Ltd. 73
Health, said there
Souvenaid's usefulness in mild
He said that the NPS report did concede
a benefit on memory.
'There have been four drugs for
dementia in the past 20 years. The most
recent 15 years old. We are desperate
for new treatment options,' Assoc Prof
'I believe it is wrong to deprive patients
of something that helps with memory.
I don't want GPs saying that the NPS says
this [Souvenaid] is a waste of time.'
The NPS report said that, 'while
Souvenaid is well tolerated and will
probably not cause harm there is
no evidence that it has any effect in
decreasing the rate of cognitive decline
or delaying AD progression'.
The NPS report also concluded that:
'there may be an effect on memory
performance in drug naive persons in
the very early stage of the disease.'
According to Souvenaid's producer,
Nutricia, it is a Food for Special Medical
Purposes (FSMP) specifically formulated
for the dietary management of early
stages of Alzheimer's disease.
The company says that reporting on the
product's clinical data, which suggest a
requirement for the product to decrease
rate of cognitive decline or a delay
in Alzheimer's disease progression,
provides an inaccurate and misleading
presentation of the evidence.
Make the dream of becoming a doctor a reality, earn
your MBBS at Oceania University of Medicine.
Attractive fee structure for our Graduate Entry Program.
Over 150 students currently enrolled and over 50
graduates in Australia, New Zealand, Samoa and USA.
Home-based Pre-Clinical Study under top international
medical school scholars, using world leading Pre-Clinical,
24/7 online delivery techniques.
Clinical Rotations can be performed locally, Interstate or
Receive personalised attention from an Academic Advisor.
OUM Graduates are eligible to sit the AMC exam or NZREX.
OCEANIA UNIVERSITY OF MEDICINE
INTERNATIONALLY ACCREDITED For information visit www.oceaniamed.org or 1300 665 343
Applications now open for courses starting in January & July - No age restrictions
BPharm to MBBS
inno ative approach
is allowing me
to realise my
Pharmacist from Cairns
Class of 2017
Nutricia says Souvenaid does not treat,
cure or prevent Alzheimer's disease,
nor is it a replacement for prescription
therapies approved for use in the
treatment of the disease.
'The company takes its responsibility
in ensuring an accurate representation
of the product and management of the
expectations on Souvenaid use very
seriously and complies with all industry
regulations and government legislation
in the education and marketing of
Assoc Prof Woodward said that
Souvenaid does work on memory,
works best with mild AD and is safe.
According to Nutricia, Souvenaid
has been specifically developed to
nutritionally support the processes
in the brain responsible for synapse
formation and as such nutritionally
supports memory function.
It said that clinical evidence for
Souvenaid in memory function is
based on two published randomised
controlled clinical trials conducted
in more than 500 patients, where
a significant change in episodic
memory measures were determined in
patients with mild Alzheimer's disease
A further study, which investigated
Souvenaid use in patients with a more
moderate stage of the disease, did not
show the same memory effects.
The authors concluded the damage to
the brain is too great to be affected by
the formation of new synapses, or that
any improvements in these patients
are too small to be detected with
An independent study funded by
the European Union, the LipiDiet,
is underway across 13 sites and is due
to be completed in 2015.
The medical food Souvenaid has been defended by a dementia specialist
against negative reports based on an NPS article published in January.
Links Archive Australian Pharmacist March 2014 Australian Pharmacist May 2014 Navigation Previous Page Next Page